GlassScriptPhysician profile
Samuel T Summers
NPI 1467474981
$6,968.14
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $805 · 2021: $1,868 · 2022: $1,509 · 2023: $1,424 · 2024: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.91 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,375.72 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $814.13 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $747.79 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Merck Sharp & Dohme LLC | $544.04 | 2019-2023 | Belsomra, Steglatro, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.83 | 2019-2023 | Jardiance |
| Abbvie INC. | $263.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $233.30 | 2019-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $220.99 | 2022-2023 | |
| Pfizer INC. | $215.35 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.81 | 2019-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $136.05 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $118.16 | 2019 | |
| Ironwood Pharmaceuticals, INC | $117.48 | 2020-2023 | Linzess |
| Biohaven Pharmaceuticals, INC. | $91.57 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.01 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $65.98 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.75 | 2021-2023 | Trintellix |
| Eisai INC. | $52.31 | 2021 | |
| Arbor Pharmaceuticals, INC. | $35.58 | 2020 | |
| Genentech USA, INC. | $23.21 | 2019-2021 | |
| Amgen INC. | $20.61 | 2024 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $19.52 | 2023 | Gvoke Hypopen |
| Shire North American Group INC | $19.42 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.00 | 2022 | |
| Optos, INC. | $15.95 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.82 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.62 | 2020 | |
| Idorsia Pharmaceuticals US INC | $11.87 | 2022 | |
| Allergan, INC. | $7.50 | 2019 | |
| Vivus LLC | $6.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.